Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
A live webcast of the presentation will be available on the “Event Calendar” page within the Investors & News section of the Company’s website at www.aadibio.com. A replay of the webcast will be available for approximately 30 days following the presentation.
About Aadi Bioscience
Aadi is a biopharmaceutical company focused on precision therapies for genetically defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In
Based on data from Aadi’s Phase 2 registrational study, AMPECT, with FYARRO, and, following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial in mTOR inhibitor-naïve solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi’s development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
SVP, Investor Relations & Corporate Communications
Source: Aadi Bioscience